Heathbridge Capital Management Ltd. Has $10.19 Million Stock Position in Zoetis Inc. (NYSE:ZTS)

Heathbridge Capital Management Ltd. cut its stake in Zoetis Inc. (NYSE:ZTS) by 0.5% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 62,550 shares of the company’s stock after selling 300 shares during the period. Zoetis comprises approximately 4.1% of Heathbridge Capital Management Ltd.’s holdings, making the stock its 14th largest holding. Heathbridge Capital Management Ltd.’s holdings in Zoetis were worth $10,191,000 as of its most recent SEC filing.

Other hedge funds have also modified their holdings of the company. Atlantic Edge Private Wealth Management LLC raised its holdings in shares of Zoetis by 482.8% in the 4th quarter. Atlantic Edge Private Wealth Management LLC now owns 169 shares of the company’s stock worth $28,000 after buying an additional 140 shares in the last quarter. Darwin Wealth Management LLC bought a new stake in Zoetis during the 3rd quarter worth approximately $31,000. First Personal Financial Services bought a new stake in Zoetis during the 3rd quarter worth approximately $33,000. Capital Performance Advisors LLP bought a new stake in Zoetis during the 3rd quarter worth approximately $33,000. Finally, Dunhill Financial LLC grew its position in Zoetis by 80.6% during the 3rd quarter. Dunhill Financial LLC now owns 168 shares of the company’s stock worth $33,000 after acquiring an additional 75 shares during the last quarter. 92.80% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of research firms recently commented on ZTS. Leerink Partnrs upgraded Zoetis to a “strong-buy” rating in a research report on Monday, December 2nd. Morgan Stanley decreased their price target on Zoetis from $243.00 to $238.00 and set an “overweight” rating on the stock in a research report on Friday. Piper Sandler decreased their price target on Zoetis from $210.00 to $200.00 and set an “overweight” rating on the stock in a research report on Monday, February 10th. Stifel Nicolaus decreased their price objective on Zoetis from $210.00 to $180.00 and set a “buy” rating on the stock in a research report on Tuesday, January 7th. Finally, Leerink Partners assumed coverage on Zoetis in a research report on Monday, December 2nd. They issued an “outperform” rating and a $215.00 price objective on the stock. One investment analyst has rated the stock with a hold rating, ten have assigned a buy rating and two have assigned a strong buy rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Buy” and a consensus target price of $214.90.

Insider Buying and Selling

In related news, EVP Roxanne Lagano sold 326 shares of the firm’s stock in a transaction on Tuesday, February 11th. The stock was sold at an average price of $171.18, for a total transaction of $55,804.68. Following the sale, the executive vice president now owns 16,107 shares of the company’s stock, valued at approximately $2,757,196.26. This trade represents a 1.98 % decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link. 0.16% of the stock is currently owned by company insiders.

Zoetis Stock Down 4.5 %

NYSE:ZTS opened at $157.54 on Friday. Zoetis Inc. has a 12-month low of $144.80 and a 12-month high of $200.53. The company has a quick ratio of 2.27, a current ratio of 3.69 and a debt-to-equity ratio of 1.26. The firm has a market capitalization of $71.08 billion, a P/E ratio of 29.61, a P/E/G ratio of 2.77 and a beta of 0.90. The stock’s fifty day simple moving average is $168.51 and its 200-day simple moving average is $178.81.

Zoetis (NYSE:ZTS) last posted its quarterly earnings results on Thursday, February 13th. The company reported $1.40 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.37 by $0.03. Zoetis had a return on equity of 51.98% and a net margin of 26.55%. The business had revenue of $2.32 billion for the quarter, compared to analyst estimates of $2.30 billion. Equities research analysts expect that Zoetis Inc. will post 5.9 earnings per share for the current year.

Zoetis Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 3rd. Investors of record on Monday, April 21st will be paid a dividend of $0.50 per share. This represents a $2.00 annualized dividend and a yield of 1.27%. The ex-dividend date of this dividend is Monday, April 21st. Zoetis’s payout ratio is presently 37.59%.

About Zoetis

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.